BioSpace News Archive

The board of directors of Eli Lilly and Company announced a 15 percent increase in its quarterly dividend.

Mr. Kollu joins GRAIL from Illumina, Inc. where he most recently served as Vice President, Global Market Development and led the teams that drove the commercial adoption of genomics in multiple applications including noninvasive prenatal testing and liquid biopsy.

Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistically significant normalization in a number of disease-associated proteins and an initial trend of a decrease compared to baseline levels in plasma Neurofilament

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 3,000 shares of Pulse Biosciences common stock to a recently hired non-executive employee under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 16, 2019.

BioAxone BioSciences, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.

Antisense Therapeutics is pleased to advise that the data from all nine participants having completed their 24 weeks of dosing in the Phase 2 clinical trial of ANP’s immunomodulatory therapy

Overall response rate (ORR) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to an immunomodulatory drug and a proteasome inhibitor, and were refractory or intolerant to an anti-CD38 antibody

The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed patients with NASH.

A paper demonstrating Spheryx’s xSight’s ability to provide new insights into complex particles has been published in the journal Soft Matter.

Dr. Patricio Stocker will continue to support Blueberries as a Senior Strategic Consultant focused on expanding the Company’s international cannabis sales and other strategic initiatives.